Navigation Links
FDA Advisers Say Avastin Shouldn't Be Used for Breast Cancer
Date:7/21/2010

TUESDAY, July 20 (HealthDay News) -- The cancer drug Avastin should no longer be used as a treatment for breast cancer, a U.S. Food and Drug Administration advisory panel voted Tuesday, saying the drug wasn't benefiting patients.

The 12 to 1 vote represented a setback for Avastin, which is the world's best-selling cancer drug, with sales last year of about $6 billion. Avastin is sold by drug maker Roche's Genentech unit, The New York Times reported.

Earlier Tuesday, the advisory committee said data suggested that at least for breast cancer, the initial data that led to accelerated approval of Avastin in 2008 for breast cancer was not borne out by subsequent studies.

The drug is also approved for lung, colon, kidney and brain cancer, the Associated Press reported.

The 13 experts convened by the FDA voted unanimously that the drug's side effects and risks outweighed benefits when used with conventional chemotherapy.

When the FDA approved Avastin for breast cancer patients in 2008, it was on the condition that Roche provide additional studies supporting evidence that the drug kept the disease from worsening for more than five months.

But two follow-up studies failed to show that same effect, and patients did not gain any survival benefits. But they did experience serious side effects, including fatigue, abnormal white blood cell counts and high blood pressure, the AP reported.

"The study shows there's very little benefit to patients with significant toxicity risks and no clear survival benefit," said Natalie Compagni Portis, the FDA advisory panel's patient representative, the news service reported.

The FDA is not bound to follow the recommendations of its advisory committees, but typically does so.

More information

To learn more about Avastin, visit the U.S. National Library of Medicine.

-- HealthDay staff

SOURCES: U.S. Food and Drug Administration; The New York Times; Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA to Broaden Disclosure on Advisers Conflicts of Interest
2. FDA Advisers Urge Stricter Regulation of Tanning Beds
3. Avastin Largely Safe for Patients With Type of Advanced Lung Cancer
4. Breast cancer cells regulate multiple genes in response to estrogen-like compounds
5. Susan G. Komen awards Case Western Reserve nearly $500,000 to study breast cancer in older women
6. Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer
7. Experts Issue New Guidelines on Breast Cancer Drugs
8. Radiation device allows for targeted breast radiation to control cancer
9. Scientists reprogram triple-negative breast cancer cells to respond to tamoxifen
10. Fish Oil Supplements Linked to Lower Risk of Breast Cancer: Study
11. Mathematical models for breast cancer detection with microwave tomography are cheaper and less risky
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional ... it has enlisted New York City-based sports and entertainment marketing firm Leverage Agency ... sponsorship opportunities for the Professional Squash Association (PSA), which includes first-time ever title ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, Kathy ... "Wonder Spice", it has been used for thousands of years. , "The West has ... author of " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, Enemy ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... provides insight into the challenges employers face in trying to balance both short-term ... employee benefits programs? Adding to the growing complexity, companies are finding that ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... documenting and diagramming network and data center assets and audio-video devices has recently ... request new equipment shapes for free and download shapes and stencils from ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Calif. , March 29, 2017  Designers of ... significantly reduce solution size by 50% and extend battery ... ) power management integrated circuit (PMIC) from Maxim Integrated ... PMIC supports a low input voltage of just 0.7V ... Air and Silver Oxide, as well as the more ...
(Date:3/29/2017)... , March 29, 2017  NuVasive, Inc. (NASDAQ: ... transforming spine surgery with minimally disruptive, procedurally-integrated solutions, ... 510(k) clearance of the CoRoent® Small Interbody™ System ... levels in the cervical spine. This marks the ... be used at up to four contiguous levels. ...
(Date:3/29/2017)... HEIGHTS, Utah , March 29, 2017 /PRNewswire/ ... ) announced today the appointment of Cynthia ... Operations.  Cyndi will be responsible for leading Dynatronics ... organization and will report to Dynatronics, CEO ... Cyndi,s appointment concludes an extensive search process conducted ...
Breaking Medicine Technology: